Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Investors can contact the law firm at no cost to learn more about recovering their losses
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
12:25pm, Thursday, 14'th Aug 2025
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
12:14pm, Thursday, 14'th Aug 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acquired
Investors in Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights - SRPT
08:45am, Thursday, 14'th Aug 2025
NEW YORK , Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during t
Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm
04:35pm, Wednesday, 13'th Aug 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
04:12pm, Wednesday, 13'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has sold 9,265,312 shares of common sto
SAN FRANCISCO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- On July 24, 2025, the European Medicines Agency (“EMA”) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta's medication i
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). S
SAREPTA STOCK: Lose Money on Your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investment? Contact BFA Law before the August 25 Legal Deadline
08:33am, Wednesday, 13'th Aug 2025
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
03:33pm, Tuesday, 12'th Aug 2025
For Sarepta Therapeutics NASDAQ: SRPT, 2025 has been nothing short of an unmitigated disaster. The firm owns the only Food and Drug Administration (FDA)-approved gene therapy for the treatment of Duch
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT
09:00am, Tuesday, 12'th Aug 2025
NEW YORK , Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
08:10am, Tuesday, 12'th Aug 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Ther
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- On July 24, 2025, the European Medicines Agency (“EMA”) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta's medication i
